Click on headlines below to download research
Turnaround strategy beginning to deliver
Vivesto | 27/06/2022
Vivesto capped off its 18-month strategic turnaround with reduced Q1 losses and a stated focus on its ‘string of pearls’ strategy to build…
Delivering on promises
Oasmia Pharmaceutical | 25/02/2022
FY21 results highlight delivery on key elements of Oasmia’s ongoing transformation. Notably, ‘rightsizing’ the business and prudent cost…
Edison Open House Healthcare 2022
Oasmia Pharmaceutical: Edison Open House Healthcare 2022 | 09/02/2022
Oasmia Pharmaceutical is a Swedish speciality pharma company focusing on its proprietary XR-17 technology platform to develop novel formulations of well-established…
Executive interview
Oasmia Pharmaceutical – executive interview | 27/01/2022
Oasmia Pharmaceutical is a specialty pharmaceutical company focused on developing new therapeutic options for patients suffering from hard-to-treat cancers.…
Rights issues secured and planned for Q122
Oasmia Pharmaceutical | 20/01/2022
Oasmia has announced it has secured a preferential, one-for-five rights issue that will raise gross proceeds of c SEK151m and should alleviate near-term…